RESULTS:
Overall, 84 patients received 679 conventional PC transfusions. Allergic transfusion reactions (ATRs) occurred in 12 (14.3%) patients transfused with 12 (1.8%) bags. Fifty-nine patients received a total of 1182 bags of RPC-M, and one patient (1.7%) had five (0.4%) ATR episodes. During the last 30 months, 58 patients were transfused 1044 bags of RPC-B, with ATRs occurring in four (6.9%) patients transfused with four (0.4%) bags. No other adverse events were observed with either RPC-M or RPC-B. CCIs (24 hr) were not significantly different for the three different PCs, and posttransfusion bleeding was not observed.
CONCLUSIONS: Plasma-replaced PC using two different PAS in children appeared to prevent ATRs accompanied without other adverse events in children. Transfusion efficacy was not significant; therefore, either of the PASs could be used with equivalent results based on the clinical situation.
T he effectiveness of washed platelet concentrate (PC) in reducing adverse reactions associated with PC transfusion, including allergic transfusion reactions (ATRs), has been clarified in previous reports. [1] [2] [3] [4] [5] Good platelet additive solutions (PASs) are essential for washing platelets. 2, 6, 7 Although successful use of PASs has been reported in several countries, 6,7 they are still not commercially available in Japan. It was recently reported that M-sol and BRS-A can be used in succession as PASs. [8] [9] [10] In Japan, these solutions are prepared by mixing commercially available products, [8] [9] [10] and their clinical application is currently being tested. 1, 3, 5 M-sol requires a mixture of five kinds of commercially available solutions and can be preserved for 1 year using a special method. 3, 8 Conversely,
BRS-A has the advantage of being easily adjusted by mixing two bicarbonated Ringer solutions with ACD-A solution. 9, 10 A comparison of washed PC using M-sol and BRS-A in vitro has confirmed that the maintenance effect of platelet quality can be achieved at the same level. 11 Washed PCs, using the M-sol or BRS-A as plasma-replaced PC (RPC-M or RPC-B), adjusted by a simplified manual method, was verified for use in pediatric patients to prevent ATRs in PC transfusion. 3, 5 According to these results, we confirmed that RPC-M or RPC-B was as effective as washed PC with G-sol in preventing ATRs and that the transfusion effect (evaluated with corrected count increment, CCI) had a similar effectiveness as regular PC in plasma. However, because CCI with washed PC with G-sol was inferior to RPC-M or RPC-B, the use of RPC-M or RPC-B was considered preferable. 3, 5 On the other hand, the superiority of RPC-M or RPC-B over the other is still unknown. Currently, although M-sol or an equivalent PAS, such as BRS-A, is recommended in the guidelines of the Japan Society of Transfusion Medicine and Cell Therapy for preparing washed PC, 5 it is unclear as to which PAS should be considered favorable. Therefore, it is necessary to verify washed PC comparing the two different PASs. We prepared washed PCs and RPCs for several years at Shinshu University Hospital. Over the years, the prepared PC products have changed from washed PC with G-sol to RPC-M and, finally, to the present RPC-B. Therefore, we performed a retrospective cohort study to compare the efficacy of ATR prevention, frequency of nonallergic events, and transfusion effect in RPCs prepared by the same method using two different PASs.
MATERIALS AND METHODS

Patient selection
A retrospective cohort study was performed between April 2013 and March 2018, and consecutive patient data were collected as representative samples. Eligible patients met the following inclusion criteria: age < 20 years; diagnosis of primary hematologic and/or malignant disease; or thrombocytopenia due to primary disease, chemotherapy, or hematopoietic stem cell transplantation. In this study, RPC was provided, regardless of the patient's history of ATRs. Based on the method of indication guidance for washed and replaced platelets and their preparation, we prepared a simplified RPC-M (i.e., resuspended PC in M-sol, which differs from the classical method with washed and replaced PC) 3, 5 as a plasma-replaced PC between April 2013 and September 2015. During the latter part of the study, we prepared RPC-B using the same methods. Therefore, there were no other differences in the comparison between the two types of RPCs, except in terms of suspended PASs and prepared periods. Because RPC could not be prepared during offshifts (i.e., night shifts, weekends, and holidays), 84 patients received transfusions of 679 untreated regular PC in plasma (P-PC transfusion) during the total study period. We defined these P-PC transfusions as the control. Characteristics of patients in each group are shown in Table 1 . The institutional review board of Shinshu University School of Medicine approved this cohort study, and written informed consent was signed by each participating patient's parent or guardian before the transfusion.
Preparation and transfusion of P-PCs, RPC-M, and RPC-B supporting medications for transfusion All transfused regular PC products were obtained from single-donor apheresis from random donors based on blood type. 12 The first aliquot of blood was discarded to prevent bacterial contamination and skin fragment contamination from the needle puncture site. [13] [14] [15] As previously described, prestorage white blood cell reduction was also performed to reduce adverse transfusion effects. 5, 16 There are six types of PC products based on the number of platelets: 1, 2, 5, 10, 15, and 20 units. 15 All patients in this study were transfused with 10 units of regular PCs in plasma, including 2 × 10 11 platelets regardless of body weight, which is the standard unit most frequently used in Japan; conversely, 1 or 2 units are used for infants or neonates. 15 All regular PCs in plasma were supplied after nucleic acid amplification test for HBV, HCV, and HIV at the Japanese Red Cross Blood Center; thereafter, the components were exposed to an irradiation of 15 to 50 Gy and used within 4 days of apheresis. 5, 16 RPCs were prepared at the Shinshu University Hospital according to the Japan Society of Transfusion Medicine and Cell Therapy guidelines. 5 BRS-A and M-sol were prepared as PASs based on a method described previously. 5,9 Premedication was not routinely administered before the transfusion of platelets in PAS M-sol and BRS-A. Intravenous medicine with antihistamine was administered 5 minutes before transfusion only for P-PC transfusions.
Evaluation of ATRs and transfusion efficacy
Reactions to the transfused platelets were recorded during the transfusion and follow-up periods, including data regarding the type of adverse reaction (ATR and nonallergic event), bleeding status on the date of PC transfusion, transfusion-associated infections, sepsis due to bacterial contamination in blood components, and transfusionrelated viral infections such as HBV, HCV, syphilis, and HIV. 3 All reactions recognized by physicians and or nurses were reported to the Division of Blood Transfusion at our institution. The types of ATRs were assessed as described elsewhere. 3 ATR was defined as the presence of at least one of the following during or within 4 hours of transfusion: maculopapular rash with/without pruritus; urticaria; pruritus; generalized flushing; localized angioedema; edema of the lips, tongue, and uvula; erythema and edema of the periorbital area; conjunctival edema; respiratory distress; bronchospasm; and hypotension. We calculated the posttransfusion CCI (24 hr) (×10 10 /L) to evaluate the transfusion effect based on a previously described method. 5 CCI was evaluated in each patient within 6 months of the initial PC transfusion for a maximum of 10 PC products. Transfusions
Volume 58, December 2018 TRANSFUSION 2953 in which aggravation of the primary disease resulted in refractoriness to transfusion, fever, infection, immunological responses such as graft-versus-host disease, disseminated intravascular coagulation, splenomegaly, or bleeding/bleeding tendency were excluded from analysis.
Quality evaluation of RPC-M and RPC-B
We also analyzed the composition and platelet activation tests of RPCs manufactured at our institution using the two different PASs (M-sol and BRS-A). We calculated platelet recovery and plasma protein reduction based on platelet counts and total protein content. Furthermore, pH and concentrations of total protein, albumin, sodium, potassium, chlorine, calcium, phosphorus, magnesium, and glucose were analyzed. We also evaluated P-selectin (CD62P) positivity as a platelet activation marker.
Statistical analysis
Fisher's exact test was used to determine the difference in characteristics of patients transfused with each PC product and to assess the differences in ATR ratio for the different PC products. ATRs were evaluated based on the frequency of incidence per patients and per bags in P-PC and RPC with M-sol or BRS-A. We used the Kruskal-Wallis test to evaluate the effect of transfusion response in terms of 24-hour CCI for each PC as well as the difference in patient ages between each group. Unpaired t-test was used to analyze the difference in the quality inspection of RPC with the two different PASs. EZR software was used for all statistical analyses. 17 Significance was defined as p < 0.05.
RESULTS ATR frequency in P-PC, RPC-M, and RPC-B
During the study period, ATRs occurred in 12 of 84 (14.3%) patients from 12 of 679 (1.8%) bags of P-PCs, in one of 59 (1.7%) patients from five of 1182 (0.4%) bags of RPC-M, and in four of 58 (6.9%) patients from four of 1044 (0.4%) bags of RPC-B. There was no difference in terms of patient background among the groups (Table 1) . Moreover, ATR frequency per patient and per product was different for the three PC products (Table 2) . ATRs from RPC-M or RPC-B were not frequent compared with those in control P-PCs for patients and products. However, there was no significant difference between RPC-M and RPC-B per patient and per product.
Transfusion effectiveness among PC products
We saw no pre-or posttransfusion hemorrhage with any of the transfused platelets, including control P-PC and RPC-M or RPC-B. CCIs (×10 10 /L) at 24 hours (median ± SD) are shown in Table 2 . The CCI of the control P-PC was higher than that of either RPC-M or RPC-B. However, the three products were not significantly different.
Frequency of nonallergic events associated with RPC
There were no nonallergic events associated with transfusion or products of the RPCs. Table 3 shows quality assessment data for RPCs with M-sol and BRS-A prepared at our institution. PCs before the plasma-replacing process with each PAS are shown as PPCs. Each score is shown as mean ± SD. Although the compositions differed among RPC products according to each PAS, the levels of platelet recovery, plasma protein reduction, and P-selectin were similar. 
Quality inspection of RPCs with M-sol and BRS-A
DISCUSSION
Although the noteworthy difference between the control group and the two groups receiving RPC-M and RPC-B is that the control patients were premedicated, we confirmed that RPC-M and RPC-B had similar ATR prevention effects and comparable transfusion effects when compared with control P-PCs without the occurrence of nonallergic events. To effectively prevent ATRs with PC transfusion, it is important to sufficiently remove PCs during the preparation of washed PCs. 2 In our manual method of RPC adjustment, it is possible to remove approximately 90%-95% of plasma proteins in the preparation process, 3, 5 but it is difficult to remove as many plasma proteins (approximately 99%) as obtained from reported automated equipment methods. 11 However, together with evidence from other reports targeting the same disease population of pediatric patients, 3,5 our manual method of RPC preparation can effectively prevent ATRs, regardless of the type of PAS (M-sol or BRS-A).
Although ATRs continued to occur, even after introducing RPC transfusions, their range was small. At our institution, after introducing RPC, no transfusion with RPC has been required to be discontinued due to severe ATR, although some patients developed minor allergic symptoms. In addition, because no other adverse events were associated with preparing RPC with M-sol or BRS-A, it was considered that the two RPCs, with two different PASs, have comparable safety profiles. Conversely, there are concerns about poor transfusion effects in performing washed PC transfusion 18 ; this is presumed to involve the loss of platelets accompanying the washing operation and shortening of lifespan due to platelet activation. 3 Although the RPCs in our study were prepared with two different PASs with use of the same method, there were no significant differences in CCI scores. Therefore, it appears that there is no influence of CCI decrease, regardless of which PAS is used. It is necessary to include magnesium, bicarbonate, potassium, calcium, glucose, etc., in PAS to maintain the quality of washed PC. 6, 11, [19] [20] [21] The contents * ATRs were evaluated by the frequency of each incidence per patient and bag between P-PC and RPC with BRS-A or M-sol. Fisher's exact test was used to assess the differences in ATR ratio for the three different PC products. Kruskal-Wallis test was used to evaluate the effect of transfusion response in terms of 24-hour CCI for each PC product. CCI 24 hr = posttransfusion corrected count increment after 24 hr.
Volume 58, December 2018 TRANSFUSION 2955 may not be the same for the two types of PAS, but all of the conditions required for PAS are satisfied. 11 in vitro verification of the quality maintenance effect of platelets is reported to be almost equal for both PASs. 11 Therefore, we are satisfied that there is no significant difference in transfusion effect between RPC-M and RPC-B, even in actual clinical practice. Although clinical influences associated with the selection of P-PC and RPC with M-sol or BRS-A did not seem to differ, except for the frequency of ATRs, actual quality inspection of each PC product was different, as shown in Table 3 . These inspections may differ according to the content of each PAS, such as with regard to the amount of anticoagulant agent, residual plasma levels, and original platelet quality. Furthermore, differences between institutions or instruments may also have an effect. Although it may be difficult to establish a standard of quality inspection for each PC product, selection of an appropriate PAS, according the pediatric patient's status or disease, should be considered in future work.
Preparing washed PCs can prevent the occurrence ATRs of transfusion by eliminating factors contained in the plasma; however, clinical characteristics associated with patient may exist that can develop ATRs. 16, 22 Our study was conducted only in children, as it has been reported that transfusion adverse reactions are more likely to occur in children than in adults, 23, 24 and particular attention should be paid to the high frequency of ATR and febrile nonhemolytic transfusion reactions accompanying PC transfusion. 16, 23, 24 Not only washed PCs, 1, 25 but attempts at preventing ATRs by introducing concentrated or plasmareduced PC (CPC) and plasma-replaced PC stored with PAS in residual plasma in 30%-35% (PC in PAS) were also reported, primarily in adults. [26] [27] [28] [29] We reviewed recent reports describing use of washed PCs, RPCs, CPCs, and PCs in PAS in comparatively large numbers of children and neonates (Table 4) . 3, 5, 26, 30, 31 Several studies have analyzed data from both pediatric and adult populations, 4, 18, 32, 33 but so far only a few investigations have targeted the pediatric population specifically. Furthermore, most studies in children were done in retrospective analyses. At present, there are very few data in children, yet no serious side effects have been reported. It is believed that a reduction in side effects can also be expected, even in children with PC formulations, including our RPC method. 3, 5, 26 Although introducing washed PC, RPC, CPC, or PC in PAS may be useful, even in children, it is essential to clarify the effectiveness of each PC formulation to prevent ATRs in prospective studies involving large populations and determining which transfusion method is suitable for which population and disease status. In contrast, similar to our study, most earlier reports were planned with the aim of prophylactic transfusions. In the future, it will be necessary to: (1) evaluate through use of multiple assessment factors, including hemostatic effects; and (2) determine whether there are differences in transfusion effects among the various PC products.
A final limitation of our study is that our data were not independent, as some of the patients included in the control group were also transfused in the M-sol and BRS-A groups. Further, a formal sample size calculation was not performed, suggesting that our study was underpowered to detect a significant difference between treatment groups. RPC using two different PASs appears to prevent ATRs without other adverse events in children. Because transfusion efficacy was not significant, either of the PASs may be used with equivalent results. Compared with conventional PAS, although M-sol has been reported to be superior in several studies, 2,5,8 a learning curve is involved. Compared with M-sol, BRS-A is easy to adjust and its noninferiority was also confirmed in RPC-B transfusion. In addition, because automated adjustment has already been introduced into clinical use, 34 further developments can be expected. Although the efficacy and safety of RPC-B transfusion, including that reported this study, has been emerging, sufficient evidence remains to be confirmed. It appears that prospective studies targeting the majority of cases will be needed to expand adaptive diseases and verify adult cases in the future.
